Key Takeaways
TB-500 is not FDA-approved for any human therapeutic indication as of October 2026.
FDA describes TB-500 as a synthetic fragment of thymosin beta-4 (Tβ4), with the amino-acid sequence LKKTETQ.
In April 2026, FDA removed TB-500 from its Category 2 listing after the nomination was withdrawn. This did not constitute FDA approval or authorization to compound the substance.
On July 23, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend TB-500-related substances for possible inclusion on the Section 503A Bulks List.
The committee’s recommendation was advisory and did not independently authorize compounding.
FDA’s briefing materials identified a lack of clinical studies and human exposure data for TB-500, leaving its potential human safety risks and effectiveness uncertain.
The 2026 World Anti-Doping Agency (WADA) Prohibited List includes thymosin beta-4 and its derivatives, including TB-500, under category S2.
Is TB-500 FDA Approved in 2026?
No. As of October 23, 2026, TB-500 is not FDA-approved for any human therapeutic use.
TB-500 is commonly described as a synthetic seven-amino-acid fragment associated with thymosin beta-4. Although researchers have studied thymosin beta-4 and related biological processes, that research does not establish that TB-500 is a safe or effective treatment for injuries, wound healing, inflammation, or any other medical condition.
FDA’s review materials for the July 2026 advisory committee meeting stated that the agency had not identified clinical studies or human exposure data for TB-500. FDA also found insufficient evidence to evaluate its effectiveness for the proposed use of wound healing.
It is important to distinguish three separate issues:
FDA drug approval: Whether a specific drug product has been approved for a medical indication.
Compounding eligibility: Whether a bulk drug substance meets the applicable requirements for use by a compounding pharmacy.
Scientific research: Whether laboratory, animal, or human studies provide evidence about a compound’s effects.
A development in one category does not automatically change the status of the others.
TB-500 FDA Status: Current Regulatory Overview
Question | Status as of October 2026 |
Is TB-500 FDA-approved? | No |
Does it have an FDA-approved human therapeutic indication? | No |
Did the July 2026 PCAC vote approve TB-500 as a drug? | No |
Did the advisory vote itself authorize routine 503A compounding? | No |
Was TB-500 removed from the earlier Category 2 listing? | Yes, following withdrawal of the nomination |
Has FDA identified human clinical evidence establishing TB-500’s effectiveness for wound healing? | No |
Is TB-500 included in WADA’s 2026 prohibited-substance framework? | Yes, as a thymosin beta-4 derivative under S2 |
The FDA’s current compounding materials and July 2026 meeting documents are the primary sources to consult when checking these distinctions.
What Changed in 2026? The TB-500 Regulatory Timeline
Two developments in 2026 attracted particular attention: the withdrawal of an earlier compounding nomination and the subsequent advisory committee review.
Understanding the order of these events helps explain why headlines about TB-500 can be confusing.
April 2026: Removal from the Category 2 listing
FDA previously listed thymosin beta-4 fragment (LKKTETQ), also known as TB-500, among bulk drug substances that may present significant safety risks in compounding.
FDA’s published information identified concerns involving potential immunogenicity, peptide aggregation, peptide-related impurities, and difficulties characterizing the active pharmaceutical ingredient. The agency also stated that it had not identified human exposure data for drug products containing the fragment.
In April 2026, TB-500 was removed from the Category 2 listing after the nomination was withdrawn. FDA’s materials nevertheless indicated that the agency intended to consider TB-500-related substances at a subsequent advisory committee meeting.
Why this matters: Removal from a Category 2 listing because a nomination was withdrawn is not the same as FDA determining that a substance is safe, approving it as a drug, or authorizing its routine use in compounded preparations.
July 23, 2026: FDA advisory committee vote
At its July 23–24, 2026 meeting, PCAC considered TB-500 free base and TB-500 acetate for possible inclusion on the Section 503A Bulks List. The proposed use evaluated by FDA was wound healing.
According to the meeting outcome reported by the National Community Pharmacists Association, the committee voted 8–6, with one abstention, to recommend the substances for inclusion.
The vote was an advisory recommendation, not a final FDA determination. It did not establish that TB-500 had demonstrated clinical effectiveness, and it did not independently permit pharmacies to compound it under Section 503A.
October 2026: What is the current position?
The key distinction remains the same: TB-500 is not FDA-approved, and the July advisory committee recommendation should not be described as drug approval or automatic authorization for compounding.
Before publishing a new regulatory update, check FDA’s official compounding list and any subsequent final determinations. A committee vote alone is not enough to establish that the legal status has changed. FDA explains that bulk drug substances used under Section 503A must meet the applicable statutory and regulatory conditions.
Does the July 2026 Vote Mean TB-500 Can Be Compounded?
No. The advisory committee’s recommendation did not, by itself, add TB-500 to the Section 503A Bulks List.
Section 503A sets conditions for compounding drug products by state-licensed pharmacists and physicians. Depending on the circumstances, a bulk drug substance must meet requirements involving an applicable USP or National Formulary monograph, its status as a component of an FDA-approved drug, or its inclusion on FDA’s permitted bulks list. Other statutory and regulatory conditions also apply.
The distinction can be summarized as follows:
Regulatory step | What it establishes |
Advisory committee vote | A recommendation to FDA |
Final FDA determination | The agency’s formal decision on the matter |
Inclusion on the applicable bulks list | May satisfy one requirement for eligible compounding, subject to all other applicable conditions |
FDA drug approval | Approval of a specific drug product for its approved indication |
These are separate regulatory steps. The July vote should not be represented as permission for routine compounding, a prescription pathway, or approval for human use.
Why Has FDA Raised Safety Questions About TB-500?
FDA’s briefing materials for the July 2026 meeting described substantial evidence gaps concerning TB-500.
The agency reported that the nomination did not include, and FDA had not identified, clinical studies or human exposure data for TB-500 through any route of administration. FDA also concluded that there was insufficient evidence to evaluate its effectiveness for wound healing.
The agency’s published compounding information identifies several potential concerns:
Immunogenicity: A peptide product may provoke an immune response, depending on its characteristics and how it is administered.
Aggregation: Peptides may form aggregates, which can affect product quality and may raise safety questions.
Peptide-related impurities: Impurities introduced during manufacturing can create additional quality and safety concerns.
Characterization challenges: Establishing the identity, composition, and consistency of a peptide active ingredient can be complex.
Limited human safety information: Without adequate human exposure data, important risks may remain unknown.
These are concerns that require scientific evaluation; they are not proof that every potential adverse effect will occur. However, they do mean that claims of established human safety should not be made without supporting evidence.
A product being advertised as “research grade” or accompanied by a laboratory certificate does not establish that it is FDA-approved or suitable for human use.
TB-500 vs. Thymosin Beta-4: What Is the Difference?
TB-500 is frequently marketed using the name thymosin beta-4, but the terms should not automatically be treated as interchangeable.
FDA identifies TB-500 as a fragment of thymosin beta-4 with the sequence LKKTETQ, comprising seven amino acids. Full-length thymosin beta-4 is a different molecule.
Feature | Full-length thymosin beta-4 | TB-500 |
Description | Naturally occurring 43-amino-acid protein | Synthetic seven-amino-acid fragment associated with the parent protein |
Sequence | Full-length protein sequence | LKKTETQ |
Research interpretation | Findings apply to the particular formulation and study examined | Findings about the full-length protein do not automatically apply to the fragment |
FDA approval | Research or clinical development does not itself establish approval | Not FDA-approved for a human therapeutic indication |
The distinction is important when evaluating published research or claims made online. Studies involving full-length thymosin beta-4 cannot automatically establish that TB-500 has the same effects, safety profile, or clinical potential.
Regulatory status must also be assessed for the exact substance and drug product rather than inferred from a related molecule.
What Does Research Say About TB-500 and Tissue Repair?
Thymosin beta-4 has been investigated for its role in actin regulation, cell migration, and other biological processes associated with tissue repair. Published studies have explored these mechanisms in laboratory and animal models.
This research provides scientific context for why thymosin beta-4 and related fragments have attracted interest. However, the existence of a plausible biological mechanism does not prove that a substance will improve healing or treat an injury in humans.
FDA’s review of TB-500 specifically found that the agency had not identified clinical evidence establishing its effectiveness for wound healing.
When assessing a research claim, consider four questions:
Was the substance studied TB-500 itself or full-length thymosin beta-4?
Was the research conducted in cells, animals, or humans?
What outcome did the researchers actually measure?
Do the findings support the claim being made, or do they only suggest a question for further investigation?
These distinctions help prevent preliminary findings from being presented as established medical benefits.
Is TB-500 Banned by WADA?
Yes. The 2026 WADA Prohibited List includes thymosin beta-4 and its derivatives, including TB-500, under category S2, which covers peptide hormones, growth factors, related substances, and mimetics. This category is prohibited at all times, both in and out of competition.
Anti-doping rules and FDA approval are separate matters. A substance can be prohibited in competitive sport without being an FDA-approved medicine.
Athletes subject to anti-doping rules should consult the current official WADA list and their relevant anti-doping organization for guidance. The fact that a compound is discussed in scientific research does not establish that it is permitted in competition.
Frequently Asked Questions
Is TB-500 FDA-approved in October 2026?
No. TB-500 is not FDA-approved for any human therapeutic indication as of October 2026. The July advisory committee vote concerned possible inclusion on a compounding list, not drug approval.
What did the FDA advisory committee decide about TB-500 in July 2026?
PCAC voted 8–6, with one abstention, to recommend TB-500 free base and TB-500 acetate for possible inclusion on the Section 503A Bulks List. The recommendation was advisory and did not independently authorize compounding.
Why was TB-500 removed from FDA’s Category 2 listing?
FDA’s published information states that TB-500 was removed after its nomination was withdrawn. That administrative change was not an FDA drug approval and did not establish that the substance was safe or effective.
Is TB-500 approved for wound healing?
No. Wound healing was the proposed use evaluated during the July 2026 advisory committee process, but FDA’s briefing materials found insufficient clinical evidence to evaluate TB-500’s effectiveness for that use.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is identified as a synthetic seven-amino-acid fragment, LKKTETQ, associated with full-length thymosin beta-4. Evidence concerning one molecule should not automatically be applied to the other.
Does research on thymosin beta-4 prove TB-500 is effective?
No. Laboratory and animal research can help scientists investigate biological processes, but it does not by itself establish that TB-500 is safe or effective in humans.
Is TB-500 prohibited in competitive sports?
The 2026 WADA Prohibited List includes thymosin beta-4 and its derivatives, including TB-500, under category S2. Athletes should consult the current official list and applicable anti-doping guidance.
Does “research use only” mean a product is FDA-approved?
No. Research-use labeling is not evidence of FDA drug approval and does not establish that a product is suitable for human use.
Where can I verify the latest TB-500 FDA status?
Consult FDA’s official drug approval records, the agency’s compounding pages, the July 2026 PCAC meeting materials, and any subsequent final FDA determinations. For anti-doping status, consult WADA’s current Prohibited List.
Conclusion: What Is TB-500’s FDA Status in 2026?
As of October 23, 2026, TB-500 is not FDA-approved for any human therapeutic indication.
The main regulatory development in 2026 was the Pharmacy Compounding Advisory Committee’s recommendation to consider TB-500 free base and TB-500 acetate for inclusion on the Section 503A Bulks List. That recommendation did not constitute drug approval or independently authorize routine compounding.
FDA’s published materials also identify significant gaps in the human evidence, including the absence of identified clinical studies and human exposure data for TB-500. Research involving full-length thymosin beta-4 may provide biological context, but it should not be treated as proof of TB-500’s safety or effectiveness.
For accurate reporting, keep the distinction between FDA approval, compounding eligibility, and scientific research clear—and verify the latest formal FDA decisions before describing any change in regulatory status.
Reference
FDA Briefing Document: https://www.fda.gov/media/193342/download?trk=article-ssr-frontend-pulse_little-text-block
FDA Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026: https://www.fda.gov/media/193711/download
FDA Panel Votes to Loosen Restrictions for Four Peptides — PharmExec: https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
TB-500 FDA Approval Status 2026: https://peptidestack.io/blog/tb-500-fda-approval-status
TB-500: Thymosin Beta-4 Fragment Evidence and Status: https://superpower.com/guides/peptides/tb-500
TB-500 Peptide: What the Research Says: https://joinmochi.com/blog/tb-500-peptide
Peptide FDA Status Tracker 2026: https://www.mdside.com/peptide-status/
Clinics — TB-500: https://peptidebase.io/peptides/tb-500
